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INTRODUCTION
Endoscopic submucosal dissection (ESD) was de-
veloped in Japan as a treatment for early gastric cancer 
(EGC). This technique allows enbloc resection of the le-
sions (1) which has demonstrated to be crucial because 
the local recurrence rate when this is not possible is of 
15 % (2). Nowadays, there is a high experience with ESD 
in Eastern countries where this technique is considered 
the gold standard treatment for EGC (3,4). Indications for 
ESD have expanded to lesions in other locations (esopha-
gus and colon) and other type of lesions (submucosal tu-
mors). However, the introduction of ESD in Europe and 
the United States of America has been and still is very 
slow. The reason to write this guideline is to familiarize 
Spanish endoscopists and gastroenterologists not only 
with the general indications of the procedure and possible 
complications but also the dedicated tools.
Received: 20-11-2013
Accepted: 30-12-2014
Correspondence: Leopoldo López-Rosés. Department of Digestive Diseases. 
Hospital Universitario Lucus Augusti. c/ San Cibrao, s/n. 27003 Lugo, Spain 
e-mail: leolopezroses@gmail.com
Fernández-Esparrach G, Calderón A, de-la-Peña J, Díaz-Tasende 
JB, Esteban JM, Zebenzuy Gimeno-García A, Herreros-de-Teja-
da A, Martínez-Ares D, Nicolás-Pérez D, Nogales O, Ono A, 
Orive-Calzada A, Parra-Blanco A, Rodríguez-Muñoz S, Sánchez-
Hernández E, Sánchez-Yagüe A, Vázquez-Sequeiros E, Vila J, 
López-Rosés L; on behalf of the Sociedad Española de Endosco-
pia Digestiva (SEED). Endoscopic submucosal dissection. Socie-
dad Española de Endoscopia Digestiva (SEED) clinical guideline. 
Rev Esp Enferm Dig 2014;106:120-132.
Vol. 106, N.º 2, 2014 ENDOSCOPIC SUBMUCOSAL DISSECTION. SOCIEDAD ESPAñOLA DE ENDOSCOPIA DIGESTIVA 121 
 (SEED) CLINICAL GUIDELINE 
Rev esp enfeRm Dig 2014; 106 (2): 120-132
INDICATIONS
The main objective of ESD is the complete resection 
of neoplastic lesions to achieve the patients cure. For this 
reason, the main indication is superficial lesions with no 
risk of lymphatic invasion. The risk of metastatic lymph 
nodes is determined by several factors related to the neo-
plasia as cellular type, size, presence of ulceration, dif-
ferentiation grade and presence of vascular and/or lym-
phatic invasion and deep of invasion. According to the 
TNM classification (5,6), early neoplasia of gastrointesti-
nal tract is located in the mucosa and submucosa layers, 
but when the submucosa is affected the risk of lymphatic 
invasion increases up to 22 %.
Esophagus
Barrett’s esophagus associated adenocarcinoma repre-
sents 50 % of all the esophageal tumors (7,8). By contrast, 
in Asia and Eastern Africa the epidermoid carcinoma is 
the histological predominant type (9). 
ESD has different indications according to the histo-
logical type of the tumor to treat (10-12): 
1.  Squamous carcinoma: Resection of lesions with a 
major diameter bigger than 15 mm, in any location 
and with any size. For lesions of minor size, the 
rates of resection in block of the EMR are similar 
to those of the ESD. In lesions of more than 20 mm, 
cure rate, absence of local recurrence and disease-
free survival of ESD reach 99 % and are superior to 
those of the fragmented EMR. On the other hand, 
the incident of perforation is 2.4 % and it is not 
significantly different from RME (1.7 %) (13,14). 
Due to an incidence of lymph nodes metastasis of 
8.5 % when the carcinoma is m3 (affectation of the 
muscularis mucosa without affectation of the sub-
mucousal layer), endoscopic treatment should be 
indicated only for m1 and m2 lesions (14) in which 
the mortality for total esophaguectomy (2  %) is 
equal or superior to the risk of metastasis, without 
difference in the long-term survival between the en-
doscopic and surgical treatment (5,6,15).
2.  Barrett’s associated adenocarcinoma: Indications 
of ESD in this group of patients can be divided in 
3 groups: a) Absolute: HGD or intramucosal adeno-
carcinoma up to m2 and lesions greater of 20 mm 
but involving less of 2/3 of the circumference of 
the esophagus; b) relative: Adenocarcinoma m3 or 
sm1 without evidence of lymph node metastasis, or 
lesion with HGD or m2 involving less than 2/3 of 
the circumference; and c) experimental: Lesions 
with sm2 invasion or deeper in high surgical risk 
patients. Finally, the risk of new areas of adenocar-
cinoma in the residual Barrett’s esophagus forces 
to perform an ablative treatment of the rest of the 
metaplastic mucosa by means of either EMR or ra-
dio frequency (16).
Recommendations: 
–  Endoscopic resection is the best method for staging 
superficial neoplasms of the esophagus, at the time 
that diminishes the rates of esophagectomy and of-
fers a safe and effective treatment to these patients. 
Level of evidence 2++. Grade of recommendation B.
–  In general, endoscopic treatment of esophageal su-
perficial neoplasms is indicated in T1s and T1a tu-
mors in which there is no difference in the long-term 
survival between the endoscopic and the surgical 
treatment. Level of evidence 1+. Grade of recom-
mendation A.
–  For esophageal squamous carcinoma less than 
15 mm the rates of en-bloc resection of EMR are 
similar to ESD with a null recurrence rate. Level of 
evidence 2++. Grade of recommendation B.
–  Contrarily, for squamous carcinoma bigger than 
20 mm, the cure rate for ESD is superior to EMR. 
Level of evidence 2++. Grade of recommendation B.
–  In squamous carcinoma, due to an increased risk 
of lymph node metastasis in m3 lesions, endoscop-
ic treatment should be indicated only for m1 and 
m2 lesions. Level of evidence 2+. Grade of recom-
mendation C.
–  In Barrett’s esophagus with superficial adenocar-
cinoma, ESD is indicated in lesions greater than 
20mm with HGD, carcinoma in situ or invasive car-
cinoma up to m2. ESD may be indicated in patients 
with high surgical risk and invasive adenocarcinoma 
affecting the first third of submucosal layer (sm1 = 
500 µm). Level of evidence 2+ Grade of recommen-
dation C.
–  In western countries, for Barrett’s esophagus asso-
ciated superficial neoplasms the results of ESD are 
similar to EMR. Therefore, the choice of the pre-
ferred treatment should be based on size of the lesion 
and the suspicion of invasion of the first third of the 
submucosal layer. Level of evidence 2++. Grade of 
recommendation B.
–  The risk of new areas of adenocarcinoma in the re-
sidual Barrett´s esophagus forces to realize an abla-
tive treatment of the rest of the metaplastic mucosa 
by means of either EMR or radiofrequency. Level of 
evidence 2++. Grade of recommendation B.
Stomach
EGC is defined as cancer limited to the mucosa or sub-
mucosa irrespective of lymphnode metastasis (17), hav-
ing an excellent prognosis after gastrectomy with lyphad-
enectomy with a 5- year survival rate of more than 90 % 
(18,19). The incidence of lymphnode metastasis in early 
gastric cancer is very low when such cancer is limited to 
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the mucosal layer (3 %), however, when cancer invades 
the submucosal layer it can increase up to 20 % (20). Con-
sequently, local and a less invasive treatment than surgery 
would be indicated in those gastric cancers limited to the 
mucosa. The purpose of establishing indication criteria 
for ESD in gastric neoplasia implies assuring a curative 
resection by complete endoscopic resection of such and 
assuming a low risk of lymphovascular involvement. 
Generally, an endoscopic resection is considered curative 
(minimal risk of lymphnode metastasis) when submu-
cosal invasion is limited to 500 µm in depth. There are 
several morphologic features of the lesions (macroscopic 
classification, mucosal and vascular pattern), which can 
enable us to predict the risk of invasion in depth.
The indications for endoscopic resection of early gas-
tric cancer traditionally established in Japan are (Table I): 
Well differentiated adenocarcinoma, lesion size < 2 cm 
if it is an elevated lesion or < 1 cm if depressed, without 
ulcer (17). Nevertheless, such criteria have been extended 
to lesions of larger size, with ulcer (21,22) and recently to 
undifferentiated type adenocarcinoma (23-26). However, 
the number of patients that fulfill such criteria and have 
lymph node metastasis is higher than 12 %, explaining the 
reported poor results (27). Regarding prognostic factors, 
in a study of 487 gastric cancers endoscopically resected, 
several features were identified as associated with no cu-
rative resection: Lesion size (> 3 cm), with ulcer and his-
topathology (diffuse type or mixed type of Lauren classi-
fication) (28). The risk of no curative resection is < 10 % 
in lesions with no ulcer, < 3 cm in diameter and localized 
in the antrum and gastric body. However, such risk is > 
40 % in lesions with no ulcer, > 3 cm and localized in 
the fornix as well as in lesions with ulcer, size larger than 
3 cm located anywhere or size < 3 cm located in the for-
nix. In such cases, surgical treatment is indicated (29).
Contraindications: Advanced age does not seem a con-
traindication (30,31). Data regarding the risk of bleeding 
in patients who do not discontinue the use of antiplatelet 
drugs before ESD is controversial (32,33). In cases with 
high risk of thrombotic disease, the necessity to continue 
treatment with such agents should not be a contraindica-
tion for the procedure (32).
Recommendations:
–  In a well differentiated type EGC, ESD is the first 
therapeutic option irrespective of size and location 
of the lesion. Evidence level 1++. Grade of recom-
mendation A.
–  Size > 3 cm, with ulcer and fornix location are as-
sociated with a higher rate of no curative resection. 
Evidence level 2+. Grade of recommendation C.
–  Advanced age is no contraindication for ESD. Evi-
dence level 2+. Grade of Recommendation C. 
–  In cases with high risk of thrombotic disease, treat-
ment with antiplatelet drugs should not be consid-
ered a contraindication for ESD. Evidence level 2-. 
Grade of Recommendation C. 
Colon and rectum
The macroscopic features of colonic lesions are estab-
lished by their type according to the updated Paris clas-
sification (34) that includes the lateral spreading tumors 
(LSTs) described by Kudo (35). This classification has a 
prognostic value as the risk of lymph node invasion in the 
colon varies depending on the macroscopic type of lesion. 
In sessile and flat lesions resection is considered curative 
when invasion into the submucosa is below 1.000 µm due 
to the low risk of lymph node metastasis (36,37), while in 
pedunculated lesions the limit is more flexible leading to 
the combination of two parameters: Invasion into the sub-
mucosa of up to 2.000 µm (38,39) and a maximum diame-
ter of invasion into the submucosa of up to 4.000 µm (38). 
Lesions considered amenable to endoscopic treatment in 
general include (Table II): a) Lesions of any macroscopic 
type; b) adenomas, intramucosal neoplasias or neoplasias 
Table I. Summary of current indications of endoscopic 
submucosal dissection in early gastric cancer
Classic 
indications
1.  Differentiated type early gastric cancer
2.  Elevated type lesions < 20 mm
3.  Depressed type lesions (no ulcer) < 10 mm
Expanded 
indications
1.  Intramucosal cancer of any size with no ulcer 
and no lymphovascular involvement
2.  Intramucosal cancer, less than 3 cm in size, no 
lymphovascular involvement, with or without 
ulcer
3.  Intestinal type cancer with submucosal 
invasion (sm1 < 500 µm), with size less than  
3 cm and without lymphovascular involvement
4.  Poorly differentiated type cancer, less than  
2 cm in size, no ulcer
Table II. Indications of endoscopic submucosal dissection 
for colorectal tumors 
1.  Large sized (> 20 mm in diameter) lesions in which en 
bloc resection using a snare EMR is difficult, although it is 
indicative for endoscopic treatment 
–  LST-NG particularly those of the pseudo-depressed type 
–  Lesions showing VI type pit pattern 
–  Carcinoma with submucosal infiltration 
–  Large and depressed type lesions 
–  Large elevated lesion suspected to be a cancer*
2.  Mucosal lesions with fibrosis caused by prior biopsy or 
peristalsis 
3.  Sporadic localized tumors in chronic inflammation (e.g. 
ulcerative colitis)
4.  Local residual early carcinoma after endoscopic resection 
*Includes LST granular mixed (LST-G mix).
LST: Lateral spreading tumor; NG: No granular; Type VI: Pattern V irregular in 
the classification of Kudo (malignant lesion but with indication for endoscopic 
resection).
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with superficial submucosal infiltration; c) lesions under 
2 cms in maximum diameter (40). Specific indications for 
ESD include (41) lesions with a high risk of adenocarci-
noma or those presenting an additional difficulty for en-
doscopic resection. 
Incidence and risk of submucosal invasion are high-
er for non-granular LSTs (LST-NG). ESD would be in-
dicated in lesions of this kind that are larger than 2 cm. 
Granular LSTs with nodules (LST-G mixed) present a 
higher risk of containing adenocarcinoma under the larger 
nodule and under pseudodepressed areas. In those cases, 
the larger nodule should be resected in a single piece or, 
for larger lesions, the whole lesion should be resected en 
bloc. Saito et al. consider ESD indicated in LST-G mixed 
larger than 3 cm (42). Other indications for ESD include 
mucosal lesions with submucosal fibrosis secondary to 
prior resections, biopsies or associated with inflammatory 
bowel disease (43). In those cases, the risk of perforation 
or leaving a residual lesion is higher if ESD is not per-
formed. Adding adrenaline to the submucosal injection 
solution could decrease the incidence of early bleeding 
of sessile and pedunculated polyps less than 1 cm (44-
46). Endoscopic resection of large colonic lesions is much 
cheaper than surgical resection (47) and implies a main-
tained quality of life for patients that are only attained 
after 1 to 5 years of convalescence in patients who have 
undergone surgery (48,49). 
After ESD with en bloc resection of a large colonic 
lesion a follow up colonoscopy is required within 3 to 
6 months to review the scar and rule out residual lesion 
and within one year due to the risk of developing new 
adenomas (50).
Recommendations:
–  ESD is indicated in LST-NG over 2 cm. Evidence 
level 1+. Grade of recommendation B.
–  Other indications for ESD include mucosal lesions 
with significant fibrosis secondary to prior biopsy or 
incomplete resection, neoplastic lesions associated 
to inflammatory bowel disease and residual super-
ficial neoplastic lesions after endoscopic resection. 
Evidence level 2-. Grade of recommendation D.
–  Adding adrenaline to the submucosal injection so-
lution may help decrease de incidence of bleeding 
though it does not prevent the use of a technique to 
precisely coagulate visible vessels arising from the 
submucosa. Evidence level 1-. Grade of recommen-
dation B. 
–  Endoscopic resection of large colonic lesions is sev-
eral times cheaper than surgical resection and im-
plies better quality of life maintenance. Evidence 
level 2++. Grade of recommendation B.
–  After ESD with en bloc resection of a large colonic 
lesion a follow up colonoscopy should be performed 
in 3 to 6 months to rule out residual lesion and in 
12 months to rule out new adenomas. Evidence level 
1++. Grade of recommendation A.
Other locations
Duodenum
Duodenal lesions susceptible to endoscopic resection 
include premalignant lesions like adenomas, benign le-
sions (Brünner hyperplasia or lipoma), and submucosal 
lesions with malignant potential like neuroendocrine tu-
mors (NET) or gastrointestinal stromal tumors (GIST) 
(51).
ESD in duodenum is a complicated procedure due to 
the existence of a very thin submucosal layer, its high vas-
cularity and also the presence of a thin muscular layer. 
All these factors increase the probability of bleeding and 
perforation, reaching the latter complication rates of 20 % 
or even more (52). There is no standardization relating to 
the size of lesions susceptible to treat. Benefits of duo-
denal ESD seem marginal comparing to EMR, with the 
exception of small-medium size encapsulated submucosal 
tumors (NET, for example), in which endoscopic ultra-
sound (EUS) has excluded muscularis propria layer in-
filtration or locoregional lymph nodes involvement. The 
most frequent complication is bleeding (53). It is impor-
tant to perform preventive vessel coagulation with coagu-
lation forceps, argon plasma or bipolar catheter. On the 
other hand, it is mandatory to perform close surveillance 
for perforation, acute or delayed, related the latter with 
excessive coagulation for bleeding treatment/prophylaxis, 
or because of a continuous exposure of the ESD ulcer to 
pancreatic juice or bile (54). Perforation rate is unaccept-
able high in some studies, reaching 36 % of the patients.
Recommendations:
–  Due to high complication rate (bleeding, perfora-
tion), duodenal ESD must be performed by highly 
experienced ESD endoscopists. Evidence level 3. 
Grade of recommendation D.
Mesopharynx and hipopharynx
ESD can be adequate for the diagnosis and treatment 
of early superficial neoplastic lesion in these locations 
(55,56). ESD in this location should be performed by 
highly experienced endoscopists in ESD. To do a precise 
delimitation of the lesion it can be useful iodine instilla-
tion. This exploration must be performed under orotra-
cheal intubation to avoid respiratory complications. Su-
pine patient position could be useful because it enlarges 
the space for endoscopy maneuvers due to maximum lar-
ynx elevation.
Recommendations:
–  Superficial meso- and hipopharynx tumors can be 
treated by ESD. These explorations must be per-
formed under orotraqueal intubation. Supine patient 
position can facilitate the procedure. Level of evi-
dence 3. Grade of recommendation D.
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Submucosal tumors
 
The origin of these lesions in muscularis propria layer is 
not a factor to preclude ESD, but perforation rates in this 
situation are higher. Average tumor size of resected speci-
mens in various studies is around 20-30 mm maximum 
and a majority of them are GIST with low grade dyspla-
sia, followed by leiomiomas and NETs. All referred resec-
tions were performed in upper digestive tube (esophagus, 
stomach and cardias), with R0 rates around 95-100 % in 
the longest series. The technique is not well standardized, 
being described the use of submucosal tunnel for resection 
of esophageal and cardiac lesions (57). There has also been 
published resections of small rectal carcinoids (< 10 mm) 
without muscularis propria involvement (58).
Recommendations:
–  Submucosal lesions arising from muscularis propria 
layer could be resected using ESD, especially those 
with a diameter < 30 mm. Level of evidence 3. Grade 
of recommendation D.
–  Esophageal or cardial submucosal lesions can be 
accessed performing a submucosal tunnel. Level of 
evidence 3. Grade of recommendation D. 
EQUIPMENT
Knives
The conventional ESD technique requires the use of 
different knives specific for each step of the procedure 
(59).The different knives for ESD share a common struc-
ture: They are plastic catheters with a metallic tip that var-
ies among different models. The vast majority of endo-
scopic knives are monopolar. Its area of contact with the 
tissue determines the cutting characteristics of the knife. 
A knife with a small contact area usually produces a deep 
cut because it generates a high current density (60).
According to the function they perform, knives can 
be classified as: Knives with cutting-clotting ability and 
knives with cutting-clotting and injection-wash ability. 
The latter allow the injection of liquid without exchang-
ing needles, achieving a faster dissection and saving time.
Knives can also be classified as covered (with insulated 
tip) and not covered. Covered knives have a cutting sur-
face which is partially protected by insulating material, 
a design aimed at restricting the direction of the cut in 
order to make dissection maneuvers safer (60). Not cov-
ered knives show their cutting area without restrictions 
and they usually have a retractable metallic tip of variable 
length. A clear superiority of a design versus the other has 
not been proven (61). In table III the characteristics of the 
most used knives are detailed.
Recommendations:
–  The choice of surgical knife depends on personal 
preferences and the familiarity with the available 
material. An objective superiority of one design over 
the rest has not been demonstrated. Level of evidence 
2-. Grade of recommendation D.
–  There are no differences between the needle-knife 
and the IT-knife regarding precision or incidence of 
complications. Level of evidence 2-. Grade of rec-
ommendation D.
–  The use of a hook-knife is especially indicated when 
confronting fibrous lesions that prevent an appropri-
ate distension of the submucous layer. Level of evi-
dence 2-. Grade of recommendation D.
–  The use of a hybrid knife could facilitate the ESD 
procedure by shortening procedure time and dimin-
ishing complications. Level of evidence 2++. Grade 
of recommendation C.
–  Utilizing a transparent cap attached to the tip of the 
endoscope is recommended, as it allows the resec-
tion to be performed more safely and with better 
control. Level of evidence 4. Grade of recommenda-
tion D.
Injection substances
In ESD, submucosal injection enables to create a 
cushion beneath the lesion and to raise the submucosal 
Table III. Characteristics of different knifes for endoscopic submucosal dissection 
Device Marking Pre-cut Cutting Dissection Hemostasis Fibrosis Beginners
Needle Knife √ √ √ √ X √ X
Flex Knife √ √ √ √ X** X √
Hook Knife √* √ √ √ X** √ X
IT Knife X X √ √ X** X √
Triangle-tip Knife √* √ √ √ X** X √***
Dual Knife √* √ √ √ X** X √
Hybrid Knife √ √ √ √ X** √ √
√ Suitable; X: Not recommended. *They can be used for pre-cut with the tip fully retracted. **Useful for coagulation in case of venous bleeding, low flow, or bleeding 
from small vessels of 1 mm. ***Difficult to use in fundus and body.
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layer, separating the mucosa from the muscularis propria 
(62,63). Normal saline (NS) 0.9 % maintains the cush-
ion for a short time and usually makes it necessary to 
perform repeated injections during the dissection phase. 
Addition of epinephrine and/or colorants such as methy-
lene blue or indigo carmine can facilitate resection by 
means of reducing the risk of bleeding and improving the 
identification of the submucosal layer. In order to prevent 
the short duration of submucosal injection effect, differ-
ent substances with higher viscosity have been used (62-
70). Hyaluronic acid (HA), is one of the most commonly 
used substances in Japan but its high cost and in vitro 
tumor cells stimulatory effect, limit its use in other coun-
tries (63-67,71-74). Glycerol or glycerin is a hypertonic 
substance obtained from mixing 10 % glycerol and 5 % 
fructose. This substance is inexpensive and easily avail-
able at any center. It has proved higher durability and 
effectiveness than NS 0.9 % (73,75). Fibrinogen has also 
been used in human studies (76). There are many other 
solutions such as hypertonic (3 %) NaCl, dextrose (20, 
30, 50 %) and hydroxypropyl methylcellulose (HPMC) 
(artificial tears) that have been used in an experimen-
tal setting. However, the description of tissue damage 
in experimental animals indicates that these solutions 
should be used with caution in humans (77-79). Also in 
an experimental level, the use of promising substances 
with higher viscosity than NS 0.9 % has been described. 
Some of them are autologous blood (69,80), PS 137-
25 (LeGoo-endoTM, Pluromed Inc, Woburn, USA) and 
2-mercaptoethanol-sulfonate (mesna). The last one has 
a chemical effect that softens the submucosa connective 
tissue (62-67,69,73,76,78,79,81,85).
Recommendations:
–  NS 0.9 % is the substance with less durability to 
maintain the submucosal cushion and it is recom-
mended the use of other substances with higher vis-
cosity. Level of evidence 1 +. Grade of recommenda-
tion A.
–  The use of NS 0.9 % should be limited to cases 
where hydrodissection technique is used. Level of 
evidence 4. Grade of recommendation D.
–  Hyaluronic acid is an ideal substance because of its 
viscosity, but its use is limited by its high cost, low 
availability in our environment and complains about 
its safety. Level of evidence 1 + +. Grade of recom-
mendation A.
–  Glycerol 10 % is a reasonable alternative because is 
cheap and easily available in our environment. Level 
of evidence 1 +. Grade of recommendation A.
–  Fibrinogen has a durability superior to NS 0.9 % but 
its use is limited by its high price. Level of evidence 
1 +. Grade of recommendation B.
–  Dextrose is a reasonable and cheap alternative in 
Western countries but there are some concerns re-
garding its safety. Level of evidence 1 -. Grade of 
recommendation B.
Electrosurgical generators
Electrosurgical units generate a high frequency current 
that allows a cutting and/or coagulation effect. This ef-
fect is due to the heat generated by the current crossing 
through the tissue, and depends on the different character-
istics of the current (voltage, time, etc.) and on the tissue 
resistance.
When using high voltage continue currents (> 200 V) 
a greater and continuous heat delivery induces a cutting 
effect. Coagulation effect (without cell bursting leading 
to tissue desiccation and coagulation) could be achieved 
both by low voltage currents or by interrupted high volt-
age currents 
The cut and coagulation effects could be used at the 
time (blend effect), anyway every cutting effect associates 
some coagulation and every coagulation effect produces 
some cutting effect (86).
New electrosurgery units have specific software that 
modulate the current and produced a specific tissue effect, 
for example the “endocut” mode from ERBE (ERBE, 
Tübingen, Germany). This mode induces tissue transec-
tion with continuous low voltage current followed by 
bursts of cutting current (87). With this technique the tis-
sue is first coagulated and then cut, with automatic cy-
cles controlled by a microprocessor that take into a count 
changes in the tissue electric resistance, and lead to a pre-
cise hemostasia and a safe cut.
Recommendations:
–  Endoscopists have to know the specific character-
istics of the electrosurgical generator that they use, 
being able to adjust the necessary settings (mode, 
kind of current, power). Evidence level 4, Grade of 
recommendation D.
–  The marking of the lesion margins is the first step for 
ESD, and soft coagulation current is used. Evidence 
level 4, Grade of recommendation D.
–  A cutting current with coagulation effect is preferred 
for the initial circumferential incision, ideally with 
endocut feature or similar. Evidence level 4, Grade 
of recommendation D.
–  For the dissection of the submucosa a coagulation 
current is usually advised for conventional knifes; 
for the Hibrid Knife system (ERBE a mixed current 
with “endocut” mode is preferred. Evidence level 4, 
Grade of recommendation D.
–  If hemostatic therapy is required, a soft coagulation 
mode or specific bipolar accessories are advised. 
Evidence level 4, Grade of recommendation D.
COMPLICATIONS AND POSTPROCEDURE 
CARE
The two main complications of ESD procedure are 
hemorrhage and perforation. They are remarkable not 
126 G. FERNÁNDEZ-ESPARRACH ET AL. Rev esp enfeRm Dig (maDRiD)
Rev esp enfeRm Dig 2014; 106 (2): 120-132
only by their frequency but also because they can sig-
nificantly affect the prognosis and therapeutic success of 
ESD (88,89). 
Hemorrhage
This complication may be classified as immediate (dur-
ing the procedure) or delayed bleeding (within 2 weeks 
or later) (89). The reported incidence of bleeding varies 
across the studies, depending on the location of the lesion. 
Thereby, the mean incidence is 2 % in colorectal lesions, 
9.3 % in gastric lesions, and 0 %-5.2 % in the esophagus 
(90-93). Immediate bleeding is considered clinically sig-
nificant when any intervention apart from the endoscopic 
treatment is needed (i.e. urgent surgery, blood transfu-
sions, vasopressor agents) or a drop in hemoglobin ≥ 2 
g/dl is detected (90,94). Delayed bleeding is clinically 
relevant when there is a decrease of hemoglobin levels 
≥ 2 g/dl, evidence of overt bleeding and endoscopic in-
tervention is needed (94). Up to 76 % of delayed bleed-
ing episodes take place within the first 24 hour after the 
procedure (90,95). In gastric lesions an increased risk of 
bleeding has been reported when the lesions are located 
either in the middle or upper third of the stomach. Elderly 
(> 80 years), procedure time, size (≥ 40 mm) and endos-
copist experience have been also associated with an in-
creased risk of bleeding (95-98). 
Prevention and management of post-ESD bleeding
1.  Endoscopic procedures. Prophylactic electrocau-
tery of large submucosal vessels during ESD has 
shown to decrease the risk of delayed bleeding up 
to 60 % (99). Performance of second-look after 
ESD is controversial (100). Electrocautery rather 
than hemoclip placement is preferred for hemo-
stasis because the latter may make the procedure 
cumbersome, preventing from continuing with the 
ESD (101). Minor oozing can be treated by elec-
trocautery with the same devices used for the ESD 
(i.e. IT knife, Flex knife...), whereas the hemostatic 
forceps (Coagrasper) are indicated in case of arte-
rial bleeding. 
2.  Pharmacological treatment. Only two randomized 
controlled trials have assessed the benefit of acid 
antisecretory drugs compared with no treatment 
prior to ESD in the prevention of delayed bleeding. 
None of them found differences between both strat-
egies (96,102). In terms of benefit after ESD, anti-
secretory drugs (PPIs) are usually recommended for 
2 months in order to prevent from delayed bleeding. 
In this setting, an 8-week treatment was found to 
be more effective than 4-week treatment. However, 
ulcer healing rate at 4 or 8 weeks of treatment seem 
to be equivalent (103). Recently, several random-
ized controlled trials compared the combination of 
PPI and mucosal protective agents (being the most 
promising rebamipide) with PPI monotherapy in 
the healing of iatrogenic ulcer after ESD. The use 
of PPI along with rebamipide might increase ul-
cer healing rates because of the synergic effect of 
both drugs (104-107). Helicobacter pylori eradi-
cation had no impact on ulcer healing at 2 months 
follow-up after the procedure (108,109). However, 
one study showed that Helicobacter pylori infec-
tion was a risk factor for ulcer recurrence after ESD 
(110). Furthermore, it is well-known that Helico-
bacter pylori eradication reduces the incidence of 
metachronous gastric cancer and thereby, it is war-
ranted in this setting (111). 
Perforation
Perforation rate is around 5 % (90,91), although in less 
experienced Western series it increases up to 20 % (92-
95). Observation of free extraluminal air after an ESD 
should not be always interpreted as a perforation leading 
to surgery. It has been described mediastinal emphysema 
development in a high percentage of patients undergoing 
esophageal ESD with no symptoms (112). 
No recognition of the muscular layer during ESD can 
precipitate a perforation. Thus, it is advisable the use of 
indigo carmine in the injection solution. It allows to clear-
ly identify the bluish plane, it means, the correct plane of 
dissection, and so that, making the procedure easier and 
safer. Depending on the perforation size and anatomical 
location, it may be applied various sealing techniques 
such as clipping (simple closure or closure with omen-
tum patch) or the insertion of a covered stent in cases of 
esophageal perforations (113).
After the endoscopic closure, the main care for patients 
includes fasting, intravenous fluid therapy and antibiot-
ics with clinical and radiological surveillance. It has been 
suggested an average duration of two days for fasting in 
gastric perforations and 4-10 days in colonic perforations. 
For colonic perforations, antibiotic therapy must be ad-
ministered for 5 to 10 days (114,115).
Cicatricial stenosis
This infrequent event is associated with large resec-
tions in gastric antrum or esophagus. Although dilation 
with bougienage or balloon have been extensively used, 
new therapeutic options have been described in order 
to prevent the development of stenosis, such as triam-
cinolone injection (116-118), preventive balloon dilation 
(119,120) or oral steroids. In two non-randomized and ret-
rospective studies, oral steroids alone or associated with 
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balloon dilation were superior to endoscopic balloon dila-
tion, reducing the number of dilations (121,122). Other 
new treatments include biodegradable or metal stent in-
sertion, topical application of mitomycin C or apposition 
of cell layers to prevent stricture formation (123-126). 
Management of antral stenosis has been based on endo-
scopic balloon dilation, with a significant risk of perfora-
tion (127,128). Finally, mucosal incision and local triam-
cinolone injection has been assayed (129).
Other complications
Other less frequent complications described in ESD are 
aspiration pneumonia, transient bacteriemia (112), phleg-
monous gastritis (130), gastric ischemia, gastric hemato-
ma (131), transmural pneumatosis, deep vein thrombosis, 
mediastinal emphysema and tension pneumomediastinum 
or pneumoperitoneum (132-135). Peritoneal carcinoma-
tosis is a rare complication and only one case has been 
published after gastric perforation. A retrospective series 
of 90 patients who underwent ESD with gastric perfora-
tion did not show this fearsome complication in the long-
term.
Recommendations:
–  Prophylactic treatment of large submucosal vessels 
during ESD decreases the risk of delayed bleeding 
and thereby it should be routinely performed. Evi-
dence level 2++. Grade of recommendation B. 
–  Second-look after ESD contributes little to the pre-
vention of delayed bleeding and therefore, it should 
not be systematically recommended. Evidence level 
1-. Grade of recommendation C.
–  Acid antisecretor agents administered before the 
procedure do not reduce the risk of delayed bleed-
ing and so that, they are not recommended. Evidence 
level 1-. Grade of recommendation C.
–  Proton pump inhibitors are superior to hista-
mine-2 receptor antagonists in prophylaxis of the 
delayed bleeding after ESD. Eight week administra-
tion of standard doses of proton pump inhibitors is 
recommended. Evidence level 1+. Grade of recom-
mendation A.
–  Treatment with proton pump inhibitors is better than 
histamine-2 receptor antagonists in order to achieve 
ulcer healing. Level of evidence 1-. Grade of recom-
mendation B. 
–  Clipping may prevent further contamination and re-
duce the risk of peritonitis, allowing conservative 
management of this complication. Evidence level 3. 
Grade of recommendation D.
–  It has been suggested two days of average duration 
of fasting in gastric perforations and 4-10 days in 
colonic perforations. For colonic perforations, anti-
biotic therapy must be administered for 5-10 days. 
Evidence level 3. Grade of recommendation D.
–  Triamcinolone injection (one or more sequential dos-
es), applied for prevention of cicatricial stenosis, can 
achieve a reduction in the incidence of stricture and 
the need for additional treatment with balloon dila-
tion. Evidence level 3. Grade of recommendation D.
–  Preventive balloon dilation was effective and with-
out adverse effects in two non-randomized clinical 
trials. With this therapy, the objective is to prevent 
stenosis developed from the initial stages of wound 
healing by periodic dilations until the complete heal-
ing of the mucosa. Evidence level 3. Grade of rec-
ommendation D.
–  Early treatment with oral prednisolone, starting at 
2-3 days post-ESD and continued for 8 weeks, alone 
or associated with balloon dilation, is superior to en-
doscopic balloon dilation. Evidence level 3. Grade 
of recommendation D.
–  Management of antral stenosis has been based on 
endoscopic balloon dilation, with a significant risk 
of perforation. Evidence level 3. Grade of recom-
mendation D.
TRAINING IN ESD
ESD is a complex and demanding technique. The skills 
required for ESD performance are commonly achieved 
after a long learning curve under expert´s tutoring (136-
137). There are recommendations regarding training in 
ESD, both in Asiatic and Western countries (138-150). 
Animal training under expert´s supervision is essential, 
since it allows the trainee to overcome some of the limi-
tations in learning ESD in real patients (150-151). Some 
experts have proposed that the best way to set up a train-
ing program is to initiate procedures in the ex vivo por-
cine gastric model. After some practice, the trainee can 
move on to the in vivo animal model, where the endos-
copist may experience a sense of reality of complications 
such as bleeding and perforation (151-153). After having 
completed several gastric cases, the trainee may move to 
different locations: Esophagus, rectum (148). There are 
some encouraging reports which have shown that a high 
level of competence, with 100 % en-bloc resection rate, 
could be achieved by non-supervised Western endosco-
pists after completing 30 ESD cases in the ex vivo gas-
tric animal model (154).
We should keep in mind that stepwise difficulty level, 
based on location and features of target lesions, seems to 
be mandatory. Not adhering to these principles may be 
associated with severe complications, which ultimately 
could be harmful for the patient and for the expansion of 
ESD (155).
Recommendations:
–  Japanese experts recommend that for ESD train-
ing, the apprentice must have: 1. Extensive knowl-
edge in clinical care; 2. Excellent skills for general 
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endoscopic procedures: i.e. a) Good experience in 
mucosal lesions assessment; b) nice ability for tar-
get biopsies; c) smooth cecal intubation technique; 
and d) broad experience in hemostatic techniques, 
polypectomy and EMR. Level of evidence 4. Recom-
mendation grade D.
–  Endoscopists should be competent in gastric ESD 
before moving to colorectal ESD. Level of evidence 
4. Recommendation grade D.
–  Japanese experts have proposed a 4-step training 
strategy: a) Initial stage: Basic knowledge for de-
tection and assessment of early gastric cancer, and 
awareness of ESD indications; b) Second stage: At-
tend several ESD procedures performed by experts; 
c) third stage: Participate as assistant for an expe-
rienced endoscopist in ESD interventions; mean-
while, the trainee should initiate a training program 
in the animal model, ideally completing the first 
30 cases within a year; and d) fourth stage: Com-
plete 30 gastric ESD under expert´s supervision, 
preferably small, distal, and fibrosis and ulcer free 
lesions. Afterwards, 40 cases should be performed 
in proximal gastric locations. Finally, 40 colorectal 
ESD should be completed, preferably in the rectum 
during the initial training period. Level of evidence 
2+. Recommendation grade C.
–  Japanese experts recommend a caseload of 
30 colorectal ESDs for a level of competence in 
this location. Level of evidence 3. Recommendation 
grade D.
–  In Europe, the recommended stepwise road map 
for ESD training would be as follows: a) Essential 
knowledge of theory regarding diagnosis and treat-
ment of early neoplasia in digestive tract; b) observa-
tion of ESD procedures performed by Asian experts; 
c) engagement in an animal training program under 
expert´s supervision for basic skills acquisition; d) 
Initiate selected human ESD cases supervised by 
experienced endoscopist; and e) continued animal 
training for skill improvement. Level of evidence 3. 
Recommendation grade D.
–  In Europe competence on ESD requires performing 
at least 10-20 every year. Level of evidence 4. Rec-
ommendation grade D.
–  In Europe, a less exhaustive ESD training program 
than the one recommended by Japanese experts ap-
pears to be good enough to acquire basic compe-
tence on this technique. Level of evidence 2. Recom-
mendation grade D.
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